Similar articles for PMID: 21536390

Year	Number of Results
2002	1
2003	1
2005	1
2007	1
2008	3
2009	10
2010	13
2011	17
2012	8
2013	12
2014	8
2015	12
2016	1
2017	2
2018	2
2019	1
2022	1
2024	0

1

Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.

Bösmüller H, Kranewitter W, Webersinke G, Rumpold H, Hackl M, Fend F. Bösmüller H, et al. Pathol Res Pract. 2011 Jun 15;207(6):399-402. doi: 10.1016/j.prp.2011.03.004. Epub 2011 May 4. Pathol Res Pract. 2011. PMID: 21536390

2

KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.

Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G. Malapelle U, et al. J Clin Pathol. 2015 Apr;68(4):265-9. doi: 10.1136/jclinpath-2014-202761. Epub 2015 Jan 21. J Clin Pathol. 2015. PMID: 25609577

3

Should oncologists be aware in their clinical practice of KRAS molecular analysis?

Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, Tonini G. Santini D, et al. J Clin Oncol. 2011 Mar 10;29(8):e206-7; author reply e208-9. doi: 10.1200/JCO.2010.32.7700. Epub 2011 Jan 24. J Clin Oncol. 2011. PMID: 21263083 No abstract available.

4

miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.

Pichler M, Winter E, Ress AL, Bauernhofer T, Gerger A, Kiesslich T, Lax S, Samonigg H, Hoefler G. Pichler M, et al. J Clin Pathol. 2014 Mar;67(3):198-203. doi: 10.1136/jclinpath-2013-201904. Epub 2013 Oct 4. J Clin Pathol. 2014. PMID: 24098024

5

Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?

Hawkes E, Cunningham D. Hawkes E, et al. Lancet Oncol. 2010 Nov;11(11):1020-1. doi: 10.1016/S1470-2045(10)70211-4. Lancet Oncol. 2010. PMID: 21051017 No abstract available.

6

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Neumann J, et al. Pathol Res Pract. 2009;205(12):858-62. doi: 10.1016/j.prp.2009.07.010. Epub 2009 Aug 12. Pathol Res Pract. 2009. PMID: 19679400

7

[The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].

Rako I, Jakić-Razumović J, Caban D, Sertić J, Katalinić D, Golem H, Plestina S. Rako I, et al. Lijec Vjesn. 2011 Nov-Dec;133(11-12):403-7. Lijec Vjesn. 2011. PMID: 22329297 Croatian.

8

Targeted therapy in first line treatment of RAS wild type colorectal cancer.

Formica V, Roselli M. Formica V, et al. World J Gastroenterol. 2015 Mar 14;21(10):2871-4. doi: 10.3748/wjg.v21.i10.2871. World J Gastroenterol. 2015. PMID: 25780283 Free PMC article. Review.

9

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Pietrantonio F, et al. Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Eur J Cancer. 2015. PMID: 25673558 Review.

10

Epidermal growth factor receptor in CRC patients in the era of the RAS.

Yanmaz MT, Demir G, Erdamar S, Keskin S, Aydin MF, Guner SI. Yanmaz MT, et al. Hepatogastroenterology. 2015 Jan-Feb;62(137):40-4. Hepatogastroenterology. 2015. PMID: 25911864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

84 results

Results by year